• Revenue down 70% to $1.71 million
• Net loss up 6% to $3.425 million
• Received $2.975 million in R&D tax incentive rebates
• Completed $4 million capital raising program

Acrux Limited, a specialty pharmaceutical company, has reported its financial results for the half-year ended 31 December 2024. The company's revenue declined by 70% to $1.71 million, while its net loss increased by 6% to $3.425 million. The decrease in revenue was primarily due to the cessation of revenue related to the procurement and sale of Active Pharmaceutical Ingredients (API) used in the commercial manufacture of Prilocaine 2.5% and Lidocaine 2.5% Cream. However, the company received $2.728 million in R&D tax incentive rebates for the year ended 30 June 2024, and an additional $0.247 million in December 2024 following the acceptance of a new Overseas Finding. The company's operating expenses increased by $0.582 million, mainly due to the timing of external research and development project expenses, interest accrued on short-term RDTI funding, and increased staff costs. During the period, Acrux made progress in expanding its portfolio of topically applied generic pharmaceutical products, with the FDA approving two ANDA submissions for Dapsone 7.5% Gel and Nitroglycerin 0.4% Ointment. The company also launched a capital raising program in December 2024, raising a total of $4.0 million before costs. The funds will be used to support the company's ongoing product development and commercialization efforts.